Background {#Sec1}
==========

Acute liver injury is one of the more common reasons for withdrawal of drugs from the market, or for interruption of their development \[[@CR1]--[@CR3]\]. NSAIDs have often been involved in liver injury \[[@CR1], [@CR4]\], and adverse hepatic reactions have been reported for most NSAIDs \[[@CR5]\]. However, general population studies have not found a clear difference between NSAIDs for hepatic reactions not leading to transplantation \[[@CR6], [@CR7]\]. Because of clusters of spontaneous reports of suspected hepatotoxicity with nimesulide, the European Medicines Agency's (EMA) Committee on Human Medicinal Products (CHMP) required an epidemiological study of NSAID-exposed acute liver failures (ALF) leading to transplantation (ALFT).

The objective of the SALT (Study of Acute Liver Transplantation) study, conducted in seven European countries (France, Greece, Ireland, Italy, The Netherlands, Portugal and the UK), was therefore to assess the population rates of ALFT without identified clinical aetiology in patients exposed to NSAIDs.

Patients and Methods {#Sec2}
====================

The SALT study was a multicentre, multinational, case-population study \[[@CR8]\] conducted in seven countries, and designed to provide estimates of the population rates of registration on transplantation lists for ALFT patients exposed to an NSAID or paracetamol (acetaminophen) within 30 days before the onset of clinical symptoms of liver disease (index date).

The study protocol was approved by the CHMP, the data protections authorities in each of the seven countries, and by Ethics Committees and Research and Development (R&D) committees as required \[[@CR9]\]. The study period for inclusion in the liver transplant registries was 2005--2007, the 3-year period preceding the last nimesulide referral to regulatory authorities. Data were collected from January 2009 to October 2011.

Centres and Cases {#Sec3}
-----------------

All 62 liver transplantation centres in the seven countries were identified. Centres dealing exclusively with cancer (one centre) or children (four centres) were excluded. The 57 eligible centres were contacted for participation. In participating centres, all adults (≥18 years of age) who were resident in the country and registered on the liver transplantation waiting lists during the 3-year study period were identified. National computerized registries were used in France, Ireland, The Netherlands and the UK for case identification, and centre registries were used for the three other countries. Anonymized information (sex, age, country resident, liver disease history and histopathology) was extracted for all patients and recorded from medical files by trained clinical research assistants, to separate chronic liver failure (CLF) from ALFT \[[@CR10]--[@CR12]\]. ALFT status was verified by the local transplant centre hepatologist, and validated by a national case classification hepatologist. For all ALFT cases, symptoms and dates, laboratory results, viral workups, autoantibodies, concomitant factors and diseases that could help to identify clinically relevant aetiologies, and drug exposure history were extracted from all available data and verified by the local hepatologist. Relevant documents were anonymized and scanned for further reference. Data were then reviewed and validated by the national case classification hepatologist, who also defined the date of onset of liver disease (index date) and classified patients as ALFT with or without an identified clinical aetiology. Typical identified clinical aetiologies were viral or autoimmune hepatitis, mushroom toxicity, vascular causes and other, as described in the medical charts. Cases with clinically defined aetiologies were not further explored for drug exposure.

In cases without clinically defined aetiologies, drug exposure, including herbals and homoeopathic medicines, was ascertained from the patient's medical files, including plasma drug concentrations if available. The timing of drug ingestion or exposure was compared with the index date, to qualify the exposure as started after the index date (drug excluded), or taken before the index date, within 7, 15, 30 or 90 days, according to international causality consensus conference criteria \[[@CR13]--[@CR16]\]. Cases without clinically defined aetiology were then classified into (i) not exposed to drugs within 30 days before the index date; (ii) exposed to any drug within 30 days before the index date, without drug overdose; and (iii) acute drug overdose, with or without suicidal intent, with demonstrated high plasma drug concentrations or documented and quantified overdose. Other exposure-time windows (90, 15 and 7 days before the index date) were used for sensitivity analyses.

Paracetamol overdoses were confirmed by the case adjudication committee, based on case description of documented overdosing (number of tablets reported taken, empty packs found with the patient, patient or family report of voluntary overdose, etc.) and/or toxic plasma paracetamol concentrations found. All other cases where paracetamol use was identified within 30 days before the index date were considered as non-overdose.

Population Exposure {#Sec4}
-------------------

Intercontinental Medical Services Ltd (IMS; London, UK) provided per-country population exposure to NSAIDs and paracetamol. These data do not include point-of-sale general outlet data for the UK, Ireland and The Netherlands. Population exposure was described as the number of units and number of defined daily doses (DDD) \[[@CR17]\] sold in each country over the 3-year period, and as treatment-years determined from the observed average daily dose as reported by prescription panels. Purely paediatric formulations were excluded and parenteral preparations were included. The IMS data were adjusted to the contribution of non-participating centres to overall transplantation activity in each country, as determined from the transplantation registries. Fixed-dose associations of NSAIDs (e.g. diclofenac + misoprostol) or paracetamol (e.g. paracetamol + codeine) were attributed to the main component of interest (NSAID or paracetamol). When paracetamol was associated with an NSAID (e.g. fixed-dose paracetamol + ibuprofen), the cases and sales were attributed to both drugs.

Event rates are reported as the number of cases per billion DDD, and as the number of cases per million patient-years of treatment, with exact 95 % Poisson confidence intervals (95 % CI).

All statistical analyses were performed using SAS software (SAS Institute, NC, USA), version 9.1.

Results {#Sec5}
=======

Participating Centres {#Sec6}
---------------------

Of 57 eligible centres, 54 (94.7 %) agreed to participate: 20/21 in France, 19/20 in Italy, 2/2 in Greece, 3/3 in The Netherlands, 2/3 in Portugal, 1/1 in Ireland and 7/7 in the UK. No specific reason was given for non-participation, other than excess workload. One centre in the UK and one in Italy that had initially accepted to participate could not provide data within the study timeframe \[[@CR9]\].

Acute Liver Failure Cases {#Sec7}
-------------------------

In the 52 contributing centres (91.2 %), 9479 patients on liver transplantation waiting lists were identified (Fig. [1](#Fig1){ref-type="fig"}), representing over 90 % of such patients in these countries. Medical files were not available for 41 patients (0.4 %), 8838 patients (93.2 %) were listed for CLF and 600 (6.3 %) for ALFT. Among the ALFT patients, the medical files were missing or incomplete for 18 patients (3.0 %) and case characteristics could not be ascertained for these 18 patients. In 219 cases (36.5 %), ALFT was explained by a defined clinical aetiology. These cases were not further explored for drug exposure. These clinical aetiologies were viral hepatitis B (34.7 %), autoimmune hepatitis (18.3 %), other viruses (7.3 %), mushroom toxicity (6.0 %), Wilson's disease (5.5 %), arterial thrombosis or Budd--Chiari syndrome (6.8 %) and various other causes (e.g. acute alcoholic or post-traumatic). Clinical aetiologies were not found in 363 cases, which were considered as clinically unexplained. Overall, 187 non-overdose cases had been exposed to at least one drug within 30 days before the index date: 40 to at least one NSAID and 147 to drugs other than NSAIDs. Two-thirds were female, mean age was around 40 years and over 81 % were eventually transplanted (Table [1](#Tab1){ref-type="table"}). ALFT was attributed to overdose in 114 cases. In 62 cases no drug exposure was found within 30 days before the index date.Fig. 1Patient disposition in the SALT study. Drug exposure (NSAID or other) was considered within 30 days before date of first clinical symptoms. *ALFT* acute liver failure leading to transplantation, *CLF* chronic liver failureTable 1Demographic characteristics of patients registered to transplantation waiting lists for acute liver failure exposed to drugs within 30 days of index date, in seven European countries (2005--2007)Patient characteristicsWith ≥1 NSAID (*n* = 40)Without NSAID (*n* = 147)Acute drug overdose (*n* = 114)Total (*n* = 301)Male \[n (%)\]11 (27.5)48 (32.7)44 (38.6)103 (34.2)Mean age at registration on transplant list \[years (SD)\]43.9 (14.6)39.1 (12.5)33.6 (10.9)37.7 (12.7)Transplanted \[n (%)\]34 (85.0)127 (86.4)83 (72.8)244 (81.1)Exposed to NSAID ≤30 days before index date \[n (%)\]40 (100.0)0 (0.0)11 (9.6)51 (16.9)Exposed to paracetamol (acetaminophen) or paracetamol combinations ≤30 days before index date \[n (%)\]22 (55.0)59 (40.1)111 (97.4)192 (63.8)Exposed to drugs other than NSAIDs ≤30 days before index date \[n (%)\]35 (87.5)147 (100.0)114 (100.0)296 (98.3)

NSAID- and Paracetamol-Exposed Cases {#Sec8}
------------------------------------

Overall, 40 cases had been exposed to a total of 43 NSAIDs within 30 days before the index date. One case had been exposed only to topical diclofenac (Table [2](#Tab2){ref-type="table"}). Thirty-five had also been exposed to other drugs, including paracetamol in 22 cases (55.0 %; Table [1](#Tab1){ref-type="table"}). Of the 147 non-NSAID and non-overdose cases, another 59 (40.1 %) had been exposed to non-overdose paracetamol within 30 days before the index date.Table 2Number of patients with acute liver failure leading to transplantation exposed to various NSAIDs as a function of time before first symptomsNSAID90 days (*n* = 44 cases)30 days (*n* = 40 cases)15 days (*n* = 37 cases)7 days (*n* = 34 cases)Celecoxib2221Diclofenac^a^7655Etodolac2222Ibuprofen14131111Indometacin1111Ketoprofen3333Ketorolac2221Meloxicam1000Naproxen2222Niflumic acid1111Nimesulide9876NSAID unspecified3332All exposures47433935^a^One case with diclofenac in topical form

Overall, 111 (97.4 %) of the 114 overdoses were attributed to paracetamol.

Event Rates {#Sec9}
-----------

The overall NSAID event rate was 1.59 (95 % CI 1.14--2.17) ALFT cases per million treatment-years (MTY), corresponding to 4.37 cases per billion DDD, with no significant difference between individual NSAID (Fig. [2](#Fig2){ref-type="fig"}). The common NSAIDs celecoxib, diclofenac, ibuprofen, ketoprofen, naproxen and nimesulide all had point estimates below 10 per MTY or per billion DDD, and an upper limit of the 95 % CI below 5 per MTY, except for naproxen (5.89) and celecoxib (7.79). Event rates for all NSAIDs pooled were almost four times higher in Ireland than in all countries pooled (Table [3](#Tab3){ref-type="table"}).Fig. 2Forest plot and event rates for exposure to an NSAID or paracetamol (acetaminophen) \[non-overdose only, or all cases including intentional and non-intentional overdose\] within 30 days before the date of the first clinical symptoms. *DDD* defined daily doses, *IMS* Intercontinental Medical Services LtdTable 3Per-country incidence rates of acute liver failure leading to transplantation exposed to any NSAID within 30 days before index date in seven European countries (2005--2007). Exposure is adjusted for centre participationCountriesNumber of DDD (IMS)Number of treatment-yearsNumber of cases exposed to an NSAIDCases per billion DDD over 3 yearsRate per million treatment-years (95 % CI)France2,526,930,7186,644,92093.561.35 (0.62--2.57)Greece591,913,3201,492,625000.00 (0.00--2.47)Ireland186,340,332488,393316.16.14 (1.27--17.96)Italy2,763,378,2628,942,220103.621.12 (0.54--2.06)Portugal532,195,1611,382,853000.00 (0.00--2.67)Netherlands473,274,972928,02148.454.31 (1.17--11.03)UK2,081,819,2765,212,248146.722.69 (1.47--4.51)*Total9,155,852,04025,091,279404.371.59 (1.14--2.17)DDD* defined daily doses, *IMS* Intercontinental Medical Services Ltd

Over the same period, 192 cases had been exposed to paracetamol within 30 days before the index date, 81 of which were without overdose, resulting in ALFT rates of 3.31 (95 % CI 2.63--4.11) per MTY for non-overdose paracetamol and 7.84 (95 % CI 6.77--9.04) per MTY when overdoses were included (Fig. [2](#Fig2){ref-type="fig"}). CIs did not overlap with those of event rates for all NSAIDs pooled.

These results remained consistent over the sensitivity analyses, such as increasing the exposure window to 90 days or reducing it to 15 or 7 days, removing NSAID-exposed cases also exposed to paracetamol or including cases with paracetamol overdose that had also been exposed to NSAIDs (data not shown).

Among the 147 ALFT cases not exposed to an NSAID, the most commonly found drug was paracetamol (40.1 %), followed by psycholeptics (Anatomical Therapeutic Chemical \[ATC\] class N05; 15.6 %) and antidepressants (ATC code N06A; 7.5 %). Cannabis was found in ten cases (6.8 %) and herbals found in seven cases (4.8 %). Other drugs mentioned include rifampicin (rifampin) and/or other antituberculosis agents, amoxicillin or omeprazole.

Discussion {#Sec10}
==========

This case-population study of liver transplant in over 227 million inhabitants could not demonstrate clearly different severe liver toxicity between the mainstream NSAIDs, and the upper limits of the 95% CIs, which indicate the greatest risk that one could confidently exclude, were similar. These results reproduce and confirm the results of population studies of less severe hepatic reactions \[[@CR6], [@CR7]\]. This study was not designed to look at ALF not listed for transplantation.

The main strength of the study is that all cases of ALF listed for transplantation are registered on transplantation lists, whether the transplant was actually done or not. Per-country identification of cases can therefore be complete. This is a prerequisite for a case-population approach \[[@CR8]\], and allows a measure of absolute risk. Participating centres represented over 90 % of all liver transplant units in the countries considered. The number of potential cases in non-participating centres was known from national or local registries, which allowed the adjustment of exposure data. Transplantations are performed only in selected and accredited centres, with expert hepatologists who are very cognizant of liver failure. We are therefore confident not to have missed any of our target cases (ALF leading to registration for transplantation) and to have the best information available on causes and exposures.

This was a study of only ALF cases that led to registration for transplantation, not of all ALF. Cases not registered for transplantation might correspond to patients older than the age limit of transplantation, which is a potential limitation of our study, or patients who die before they can be listed for transplantation or who are not considered for transplantation for other reasons. If the reason for not transplanting is not related to exposure to the drugs of interest, missing these cases that might have been registered for transplantation but that were not transplanted would decrease the overall study power, but would not bias the results. Since the drugs were all in the same therapeutic class, it is unlikely that differential exposure to any individual drug would be a reason to decide to transplant or not to transplant a patient. The multi-country nature of the study can also compensate for any country-specific drug-related bias.

Other studies have included patients with less-severe ALF and found similar results to ours \[[@CR6], [@CR7]\]. Because less-severe hepatic injuries might be hospitalized in many different settings, there is no possibility of the exhaustive countrywide retrieval of cases that are necessary for the case-population design used here.

Under-ascertainment of actual drug exposure in patients, related to poor history taking in transplant centres, might spuriously decrease the numerator. The medical history of liver transplant patients is usually thoroughly explored before transplantation, including information from general practitioners (GPs) and other sources. For confidentiality reasons, we could not seek further information from GPs or patients; however, from our expert board it is unlikely that relevant information from the GP would be missing from the hospital files. Nevertheless, patients may have had exposures or diseases unknown to the GP \[[@CR18]--[@CR20]\]. This might be especially true for over-the-counter (OTC) drugs such as paracetamol or ibuprofen. This could artificially reduce the event rates for these drugs, but would not change the findings of the study concerning prescription NSAIDs.

Facing an otherwise unexplained ALF, clinicians might tend to look for evidence of exposure to 'known' hepatotoxic drugs such as nimesulide, diclofenac or paracetamol more than exposure to other drugs, including other NSAIDs. These may then be under-ascertained and bias the result in disfavour of known hepatotoxic drugs (notoriety bias). On the other hand, because adverse hepatic reactions have been reported for many NSAIDs \[[@CR5]\], there is little reason that any one would have been reported more or less often than others. For paracetamol, the uncertainty lies between underreporting of OTC paracetamol and the search for hepatotoxic drugs. Underreporting of OTC use would reduce the apparent risk of paracetamol, which in this study would be a conservative bias and could not explain the 2-fold higher event association with paracetamol.

The choice of the 30-day exposure window was based on causality assessment methods from consensus conferences \[[@CR13]--[@CR15]\], which state that it would be very unlikely that a drug stopped more than 30 days before the onset of first symptoms might be associated with acute hepatotoxicity, especially since NSAIDs such as ibuprofen, diclofenac or nimesulide have half-lives ranging from 2 to 8 hours.

Treatment duration was very rarely recorded, even for those patients who were still on the medication at the time of symptom onset, so we cannot describe a duration-of-treatment effect. Considering the small number of cases with individual drugs, it might have been unwise to attempt any kind of systematic case description. This should probably come from studies of less severe but more frequent cases. This assumes that the different NSAIDs included in the analysis were expected to be used in subpopulations with similar risk factors of developing ALF. Ibuprofen might be used in younger patients for a shorter duration of time \[[@CR21]\], which could contribute to a lower event rate. The other NSAIDs are used in mostly similar populations in countries where this information exists \[[@CR21], [@CR22]\].

Because we did not have access to the actual number of users in each country, we chose to use overall population exposure measures, in DDD or treatment-years. The same data source (IMS) was used for all countries and all NSAIDs or paracetamol. This includes all sales to pharmacies, including OTC resale, but not sales in supermarkets, convenience stores or petrol stations, which are possible in the UK, Ireland or The Netherlands. These artificially lower exposures and may result in higher apparent event rates in these countries for drugs sold in such outlets, mostly ibuprofen and paracetamol. This would not affect drugs that are prescription-only in the countries considered, such as diclofenac, ketoprofen or nimesulide. In France, OTC ibuprofen and paracetamol are sold only in pharmacies, so that the sales data for these are complete.

Sales data were adjusted for the non-contributing transplantation centres. Since the same source was used for all drugs in all countries, any distortion would affect all drugs in the same manner, preserving the internal validity of the results. Expressing the results per DDD based on theoretical daily treatment as used for drug statistics, or as patient-years based on average prescribed dose, does not materially change the results. In this study we did not have access to the absolute number of patients treated with individual drugs, only quantities converted to DDD. This unit provides a standardized way to measure per country or per capita drug use that can be compared across and between drugs and drug families. Treatment-years are calculated from the average daily dose observed in patient panels in each country, making them perhaps a better metric because they take into account different drug prescription patterns between countries and drugs. If all drugs are used in more or less the same way, then the treatment-years are directly related to the number of patients and average prescription, and treatment-years might be an appropriate proxy for the number of users. These crude measures have the advantage of simplicity and robustness, but the inconvenience of being rather insensitive.

Event rates for NSAIDs were less than ten cases per million patient-years of treatment or billion DDD sold over 3 years, all NSAIDs combined or for individual drugs, consistent with other data for fulminant hepatitis \[[@CR23]\]. This makes any attempt to measure more precisely possible differences among individual NSAIDs very difficult. Considering the small number of cases, and the very non-specific nature of liver pathology at the advanced stage of liver failure in these patients, it was not possible to identify specific pathological features, risk factors for one or other of the NSAIDs, or elements suggesting mechanisms of severe liver injury. From other studies, no specific mechanism of toxicity has been identified for individual NSAIDs other than diclofenac and sulindac \[[@CR24]--[@CR27]\]. Nevertheless, these two drugs did not seem to be associated with excess risk of hepatotoxicity in the present study. In other registries of drug-induced liver injury (DILI), antibiotics seem to be more often associated with DILI than NSAIDs. This might be related to the recording of less severe toxicity or cholestatic liver disease not leading to transplantation, which would not appear in our study. It might also be related to real differences in drug toxicity between countries, for unidentified reasons.

We found a 2- to 3-fold higher event rate for non-overdose paracetamol compared with all NSAIDs pooled, based on the same criteria used for NSAIDs. This has not been generally described, paracetamol toxicity being reported as essentially associated with overdose. There may be several reasons for this: OTC paracetamol is usually not recorded in claims databases or in medical databases; and in field studies there may be under-ascertainment or dismissal of non-overdose paracetamol exposure. The hepatotoxicity of paracetamol has been generally thought to be confined to overdose \[[@CR3], [@CR28], [@CR29]\], including staggered overdoses \[[@CR30]\], although there have been studies showing an association of paracetamol at therapeutic doses and liver injury \[[@CR3], [@CR31], [@CR32]\] in addition to case reports \[[@CR33]\]. Others dispute this association \[[@CR34]--[@CR36]\].

We found paracetamol in 40 % of the cases of ALFT where any drug was found during the 30 days before the first symptoms (more often than any other drug). When this is compared with population exposure, in DDD or treatment-years, the event rates were 2- to 3-fold greater than with NSAIDs. This may be purely coincidental, and in most cases there may be another explanation \[[@CR35]\], but non-overdose paracetamol might also play a direct or indirect causal role \[[@CR31], [@CR33]\], maybe through depletion of glutathione, reducing liver detoxification capabilities \[[@CR37], [@CR38]\]. Because paracetamol may be bought OTC in supermarkets and petrol stations (albeit in very small quantities), and this would not be captured in the UK, Ireland or The Netherlands, there could be concern about overestimation of the event rate for paracetamol. However, considering the event rate differential with all NSAIDS, the fraction thus missed would have to be half of the overall sales of all seven countries to explain the difference in event rates between paracetamol and all NSAIDs pooled. Such a hypothesis would appear to be somewhat far-fetched, especially since in other countries all sales are captured.

Because patients in pain require medication to alleviate the pain, the choice is not really between NSAID and no medication, but between one analgesic and another. In this case, avoiding any one of the mainstream NSAIDs because of excess reporting of liver toxicity would shift the use and risk to another NSAID. This would probably not change the individual per-patient risk of severe hepatic failure, which is essentially the same for the mainstream NSAIDs. Shifting to paracetamol might actually double the risk of ALF, even when overdose is not considered.

Conclusion {#Sec11}
==========

From this seven-country, 3-year, case-population study of ALF leading to registration on transplantation lists, it appears that the presence of an NSAID within 1 month before the first symptoms of ALFT is rare, and that there is evidence of a relevant difference between the different mainstream NSAIDs for population-time exposure rates. The event rate of ALFT exposed to non-overdose paracetamol was more than 2-fold higher than for all NSAIDs pooled, and higher than most individual NSAIDs.
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